Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 2/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6630621 | 0.85 | METAP1 (0.51) | METAP1CYP19A1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL6630617 | 0.84 | METAP1 (0.50) | METAP1CYP19A1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL7340887 | 0.82 | METAP1 (0.48) | METAP1CYP19A1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL8003063 | 0.81 | METAP1 (0.71) | METAP1CYP19A1ACHEHTR1ASIGMAR1 | |
| SCHEMBL2125675 | 0.81 | METAP1 (0.71) | METAP1CYP19A1ACHEHTR1ASIGMAR1 | |
| SCHEMBL7345539 | 0.80 | METAP1 (0.46) | METAP1CYP19A1ALDH1A1SMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL2125507 | 0.79 | METAP1 (0.72) | METAP1CYP19A1 | |
| SCHEMBL7344655 | 0.79 | METAP1 (0.45) | METAP1CYP19A1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL7094657 | 0.78 | METAP1 (0.39) | METAP1CYP19A1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL7337797 | 0.77 | CYP19A1 (0.44) | METAP1CYP19A1ALDH1A1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | disclosed |
| EP-1317459-A1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | AstraZeneca AB (SE) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002020530-A1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | GYS1, GYS2, PYGL | METAP1 3110/4885CYP19A1 2176/4885ALDH1A1 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.